Abstract
Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.
Original language | English |
---|---|
Article number | ARTN 1759720X19883973 |
Number of pages | 6 |
Journal | Therapeutic Advances in Musculoskeletal Disease |
Volume | 11 |
DOIs | |
Publication status | Published - Oct 2019 |
Keywords
- benefit-risk ratio
- biologics
- denosumab
- romosozumab
- POSTMENOPAUSAL WOMEN
- RHEUMATOID-ARTHRITIS
- CERTOLIZUMAB PEGOL
- ROMOSOZUMAB
- PREVENTION
- INFLIXIMAB
- FRACTURES
- DENOSUMAB
- DISEASES
- SAFETY